{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:58:04Z","timestamp":1761631084726,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: This study applies a Physiologically Based Biopharmaceutics Modeling (PBBM) framework to predict the bioavailability (BA) and bioequivalence (BE) of apixaban, a borderline BCS Class III\/IV drug. It investigates how formulation factors, such as particle size, granulation method, and dissolution conditions, affect apixaban\u2019s in vivo behavior under fasting conditions. Methods: A PBBM approach was developed by integrating physicochemical, formulation, and drug-related parameters to simulate dissolution and absorption using a middle-out strategy for combining in silico, in vitro, and in vivo data. The Noyes\u2013Whitney equation was used to predict dissolution influenced by particle size, granulation type, and in vitro dissolution conditions. This information was added to a compartmental absorption model of the gastrointestinal track connected to a classical compartmental model characterizing apixaban\u2019s disposition. Results: The study validated the apixaban PBBM predictions by comparing simulated and observed pharmacokinetic profiles across several doses and immediate release formulations (solution and tablets) administered through the oral route. Results demonstrated acceptable prediction accuracy for BA and BE under various conditions. The model\u2019s simulations identified a dissolution safe space, enabling regulatory and development insights into acceptable formulation characteristics. Conclusions: These findings highlight the potential of PBBM in streamlining drug development, reducing clinical studies, and supporting regulatory decisions. Specifically, for apixaban, the study demonstrated that particle sizes below 120 \u00b5m ensure BE with reference formulations, while formulations with faster dissolution rates, such as smaller particle sizes, align closely with BCS biowaiver criteria. This research emphasizes PBBM as a valuable tool for optimizing drug quality and lifecycle management.<\/jats:p>","DOI":"10.3390\/pharmaceutics17030382","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T04:34:43Z","timestamp":1742272483000},"page":"382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Physiologically Based Biopharmaceutics Model of Apixaban for Biopharmaceutics Risk Assessment"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-4840","authenticated-orcid":false,"given":"Paulo","family":"Paix\u00e3o","sequence":"first","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, 1649-004 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2127-8605","authenticated-orcid":false,"given":"Zvonimir","family":"Petric","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, 1649-004 Lisboa, Portugal"}]},{"given":"Jos\u00e9 A. G.","family":"Morais","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, 1649-004 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.xphs.2020.10.059","article-title":"Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report","volume":"110","author":"Mitra","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_2","unstructured":"European Medicines Agency (2018). Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation."},{"key":"ref_3","unstructured":"Food and Drug Administration (2020). The Use of Physiologically Based Pharmacokinetic Analyses\u2014Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls."},{"key":"ref_4","unstructured":"ICH (2024). M13A\u2014Bioequivalence For Immediate Release Solid Oral Dosage Forms, ICH."},{"key":"ref_5","unstructured":"ICH (2024). M15\u2014General Principles For Model-Informed Drug Development, ICH."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11095-022-03373-0","article-title":"Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development","volume":"40","author":"Wu","year":"2023","journal-title":"Pharm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1208\/s12248-023-00837-y","article-title":"Biopharmaceutics Risk Assessment-Connecting Critical Bioavailability Attributes with In Vitro, In Vivo Properties and Physiologically Based Biopharmaceutics Modeling to Enable Generic Regulatory Submissions","volume":"25","author":"Ahmed","year":"2023","journal-title":"AAPS J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1021\/acs.molpharmaceut.4c00758","article-title":"PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report","volume":"21","author":"Heimbach","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12249-023-02521-y","article-title":"Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective","volume":"24","author":"Kollipara","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","article-title":"Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa","volume":"50","author":"Pinto","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_12","unstructured":"Patel, J., Frost, C., Jia, J., and Vema-Varapu, C. (2011). Apixaban Formulations. (No. EP3246021A1), U.S. Patent."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40256-015-0157-9","article-title":"Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa","volume":"16","author":"Vakkalagadda","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","first-page":"153","article-title":"Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects","volume":"10","author":"Frost","year":"2018","journal-title":"Clin. Pharmacol."},{"key":"ref_16","unstructured":"D\u2019Argenio, D.Z., Schumitzky, A., and Wang, X. (2009). ADAPT 5 User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software, B.S. Resource."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","article-title":"A compartmental absorption and transit model for estimating oral drug absorption","volume":"186","author":"Yu","year":"1999","journal-title":"Int. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2012.03.019","article-title":"Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model","volume":"429","author":"Paixao","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1021\/acs.molpharmaceut.9b00870","article-title":"Physiologically-Based Pharmacokinetic Model on the Oral Drug Absorption in Roux-en-Y Gastric Bypass Bariatric Patients: Amoxicillin Tablet and Suspension","volume":"16","author":"Montanha","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1016\/j.xphs.2020.05.019","article-title":"Suitability of the z-Factor for Dissolution Simulation of Solid Oral Dosage Forms: Potential Pitfalls and Refinements","volume":"109","author":"Dressman","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1208\/s12248-020-00548-8","article-title":"Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach","volume":"23","author":"Pepin","year":"2021","journal-title":"AAPS J."},{"key":"ref_23","unstructured":"European Medicines Agency (2014). Guideline on the Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1M141","article-title":"Comparing generic and innovator drugs: A review of 12 years of bioequivalence data from the United States Food and Drug Administration","volume":"43","author":"Davit","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/mp100053q","article-title":"The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation","volume":"7","author":"Tsume","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_26","unstructured":"ICH (2019). M9\u2014Biopharmaceutics Classification System-Based Biowaivers, ICH."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/3\/382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:30Z","timestamp":1760028930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/3\/382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["pharmaceutics17030382"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17030382","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}